SAG (1.0 mM) predominantly stimulates osteogenesis at the borders of defects and leads to a notable increase in BV/TV at the eight-week time point in CD-1 mice^[4].

SAG (15-20 mg/kg; i.p.) predominantly induces dose-dependent pre-axial polydactyly in mice^[5].

SAG (0.1 nM-100 μM; 30 h) stimulates firefly luciferase expression in Shh-LIGHT2 cells, with an EC50 of 3 nM, followed by suppression of expression at higher concentrations^[1].

SAG (1-1000 nM; 1 h) competes with BODIPY-cyclopamine for Smo binding in Cos-1 cells expressing Smo, yielding an apparent dissociation constant (Kd) of 59 nM for the SAG/Smo complex^[1].

SAG (100 nM) counteracts the inhibitory effect of Robotnikinin on ShhN-induced pathway activation^[2].

SAG (250 nM; 48 h) markedly enhances the expression of SMO mRNA and protein in MDA-MB-231 cells^[3].

SAG (250 nM; 24 and 48 h) upregulates CAXII mRNA expression in MDA-MB-231 cells under both normoxic and hypoxic conditions^[3].

SAG (250 nM; 24 h) enhances the migration of MDA-MB-231 cells^[3].